

Medical Comorbidities

Annie Lévesque, MD, MSc

Assistant Professor, Department of Medicine, Department of Psychiatry
Mount Sinai West Hospital, Icahn School of Medicine

The ASAM Review Course of Addiction Medicine

July 2022

Financial Disclosures

Annie Lévesque, MD, MSc

No Disclosures



Learning Objectives

List common co-occurring medical complications associated with drug use and methods for prevention and treatment.

Presentation Outline

Routine and preventive care

- ◆ History
- ◆ Physical examination
- ◆ Labs

Comorbidities and consequences of SUD

- ◆ Cardiovascular
- ◆ GI
- ◆ Pulmonary
- ◆ Renal
- ◆ Infectious
- ◆ Neuro
- ◆ Traumatic injuries
- ◆ Endocrine

General Medical Evaluation

Routine/preventive care follows national guidelines (USPSTF)

History and physical evaluation includes categories of assessment employed for all patients, with special focus on the following:

History

- ✦ Social and family history
- ✦ Emergency Department visits or hospitalizations related to substance use
- ✦ Psychiatric history
- ✦ Substance related risk behaviors

Physical evaluation

- ✦ Vitals
- ✦ Observation: signs of intoxication/withdrawal
- ✦ ENT: pupils, oral cavity, nasal septum
- ✦ Heart: murmur
- ✦ Abdomen: liver
- ✦ Extremities: injection sites, tremors

General Medical Evaluation

Health maintenance labs:


- ☀ Complete blood count
- ☀ Metabolic panel
- ☀ Liver function
- ☀ Lipid panel
- ☀ HBA1C
- ☀ HIV, HBV, HAV, HCV, PPD, RPR
- ☀ Vitamin D

Cardiovascular

- ☀️ **TOBACCO** → Atherosclerosis, HTN, CAD
- ☀️ **STIMULANTS** → Chest pain, HTN, arrhythmia, cardiomyopathy, MI (avoid beta-blockers)
- ☀️ **OPIOIDS** → Methadone can increase QTc
- ☀️ **ALCOHOL** → Cardiomyopathy, Afib, HTN, CAD

Cardiovascular

Alcohol consumption and all-cause mortality



Moderate alcohol intake and cardiovascular benefits

- ◆ Association Causality
- ◆ Antioxidant (phenolic and flavonoid components red wine), antithrombotic, anti-inflammatory
- ◆ No recommendation to drink alcohol for health benefits

Gastrointestinal

PANCREATITIS

- ◆ Abdominal pain
- ◆ \uparrow amylase/lipase $>$ 3 times upper limit
- ◆ $>$ 100g ETOH per day for 5-10 years

Acute

- ◆ Acute inflammatory process
- ◆ 28% of cases in women and 59% in men due to ETOH

Chronic

- ◆ Progressive inflammatory changes
- ◆ Permanent structural damage
- ◆ Impairment of endocrine/exocrine functions

Gastrointestinal

Alcoholic liver disease

☀ Risk Factors:

- ☀ Amount of alcohol use
- ☀ Female gender
- ☀ Genetic
- ☀ Obesity
- ☀ Viral hepatitis
- ☀ Hepatotoxins

Gastrointestinal

Alcoholic liver disease

Steatosis


- ◆ Anorexia, nausea, RUQ pain
- ◆ Potentially fully reversible

Alcohol-related hepatitis

- ◆ Jaundice, bruising, ascites, encephalopathy
- ◆ $AST/ALT \geq 2:1$, \uparrow bilirubin, \uparrow INR
- ◆ Maddrey score ≥ 32 corticosteroid
- ◆ Pentoxifylline may decrease mortality


Cirrhosis

- ◆ Late stage of hepatic fibrosis
- ◆ Irreversible



Gastrointestinal

Typical symptoms of liver cirrhosis



Symptoms of liver cirrhosis

- General malaise, fatigue
- Anorexia / weight loss
- Feeling of enlarged abdomen
- Swollen abdomen / legs
- Nose bleed / bleeding from lower limbs
- Jaundice / itch
- Hand tremors

Physical findings

- Skin pigmentation
- Xanthoma
- Spider angioma
- Palmar erythema
- Finger clubbing (hepatopulmonary syndrome)
- Caput medusae
- Gynecomastia
- Fever
- Hepatoceleoma
- Hepatic halitosis (dimethyls-ulphide, ketons in the expired breath)
- Jaundice
- Ascites, lower thigh edema
- Hepatic encephalopathy
- Bleeding plaque / purpura

Akuko Wakuta etc., Hepatobiliary and pancreas, 73(6), 979-984, 2016 (Partially modified)

Gastrointestinal

CANNABIS HYPEREMESIS SYNDROME

- ☀ Episodic nausea, vomiting, and abdominal pain
- ☀ Relieved by exposure to hot water
- ☀ Generally seen in at least weekly users (more often daily users) for at least a year
- ☀ Unclear pathophysiology
- ☀ Treatment: topical capsaicin on abdomen can relieve acute symptoms, cannabis cessation

Pulmonary Complications

Tobacco

COPD
Asthma
Lung Cancer

Cannabis

Exacerbation of COPD
and asthma

Opioids

Respiratory
depression
Sleep apnea

Cocaine

Pneumothorax
“Crack lungs”
Chronic toxicity

Alcohol

Aspiration pneumonia
Ascites
Hepatopulmonary
syndrome

Sedative-hypnotic

Respiratory
depression

Inhalants

Respiratory
depression
Barotrauma
Pulmonary edema

Amphetamines

Pulmonary
hypertension
Pulmonary edema

Anabolic steroids

Pulmonary embolism

Renal

KETAMINE-INDUCED UROPATHY

- ☀ Urge incontinence, decreased bladder compliance, decreased bladder volume, detrusor overactivity, hematuria
- ☀ Rarely hydronephrosis or papillary necrosis
- ☀ Some injuries are permanent, other improve with medical and surgical treatment
- ☀ Mechanism unclear: possible irritation from contact of metabolite with bladder and ureteral mucosa

Infectious Complications - Endocarditis





Image from: Marks LR, Nolan NS, Liang SY, Durkin MJ, Weimer MB. Infectious Complications of Injection Drug Use. *Medical clinics of North America*. 2022;106(1):187-200. doi:10.1016/j.mcna.2021.08.006

Infectious Complications - Endocarditis

Endocarditis in people who inject drugs is associated with rising mortality



Infectious endocarditis should be suspected in patients with fever and risk factors:

- ◆ IV drug use
 - ◆ Tricuspid valve
 - ◆ IV cocaine use - vasospasm
- ◆ IV lines
- ◆ Prior IE
- ◆ Prosthetic valve, hx of valvular disease
- ◆ Cardiac device
- ◆ Immunosuppression
- ◆ Recent dental or surgical procedure

Treatment: Antibiotic therapy +/- valve surgery

Infectious Complications

Sharing of contaminated material is the main driver of HIV and HCV infections among PWID

- ◆ Needles
- ◆ Auxiliary injection material: dilution water, filters, cookers, backloading, frontloading
- ◆ Crack pipes



Infectious Complications

HIV	
Type of exposure	Risk of infection (%) ¹
Anal receptive	0.5 to 3.38
Anal insertive	0.06 to 0.16
Vaginal receptive	0.08 to 0.19
Vaginal insertive	0.05 to 0.1
Mother-to-child	15 to 45
Accidental puncture	0.33
Sharing of injection equipment	0.7 to 0.8

HCV	
Type of exposure	Risk of infection (%) ^{2,3}
Blood transfusion	Negligible since 1990
Sexual exposure	Low
Sharing of personal items	Low
Tattoo and piercing	Low
Mother-to-child	5 to 6
Accidental puncture	1.8
Sharing of injection equipment	2.5 to 5

- ◆ HIV and HCV viruses can survive **several weeks** outside of human body
- ◆ Viability of virus varies based on virus concentration, medium in which virus is contained, moisture, temperature, sunlight



¹Public Health Agency of Canada, HIV Transmission Risk: A Summary of Evidence,

²Noel L et al. INSPQ 2016.

³O'Brien et al. Transfusion 2007


Infectious complications – Hepatitis C

☀ Most patients with HCV in North America acquired disease through **IV drug use**




Infectious Complications – Hepatitis C

- ☀️ **Annual HCV testing** is recommended for PWID with no prior testing or past negative testing and subsequent injection drug use
- ☀️ Clinical trials among PWID who report current IDU at the start of HCV treatment and/or continued use during therapy demonstrate **SVR rates** approaching **95%**



Infectious Complications –PrEP for HIV



Infectious Complications –PrEP for HIV

	Sexually-Active Adults and Adolescents ¹	Persons Who Inject Drug ²
Identifying substantial risk of acquiring HIV infection	Anal or vaginal sex in past 6 months AND any of the following: <ul style="list-style-type: none"> • HIV-positive sexual partner (especially if partner has an unknown or detectable viral load) • Bacterial STI in past 6 months³ • History of inconsistent or no condom use with sexual partner(s) 	HIV-positive injecting partner OR Sharing injection equipment
Clinically eligible	<p style="text-align: center;"><u>ALL OF THE FOLLOWING CONDITIONS ARE MET:</u></p> <ul style="list-style-type: none"> • Documented negative HIV Ag/Ab test result within 1 week before initially prescribing PrEP • No signs/symptoms of acute HIV infection • Estimated creatinine clearance ≥ 30 ml/min⁴ • No contraindicated medications 	
Dosage	<ul style="list-style-type: none"> • Daily, continuing, oral doses of F/TDF (Truvada®), ≤ 90-day supply <p style="text-align: center;">OR</p> <ul style="list-style-type: none"> • For men and transgender women at risk for sexual acquisition of HIV; daily, continuing, oral doses of F/TAF (Descovy®), ≤ 90-day supply 	
Follow-up care	<p><u>Follow-up visits at least every 3 months to provide the following:</u></p> <ul style="list-style-type: none"> • HIV Ag/Ab test and HIV-1 RNA assay, medication adherence and behavioral risk reduction support • Bacterial STI screening for MSM and transgender women who have sex with men³ – oral, rectal, urine, blood • Access to clean needles/syringes and drug treatment services for PWID <p><u>Follow-up visits every 6 months to provide the following:</u></p> <ul style="list-style-type: none"> • Assess renal function for patients aged ≥ 50 years or who have an eCrCl < 90 ml/min at PrEP initiation • Bacterial STI screening for all sexually-active patients³ – [vaginal, oral, rectal, urine- as indicated], blood <p><u>Follow-up visits every 12 months to provide the following:</u></p> <ul style="list-style-type: none"> • Assess renal function for all patients • Chlamydia screening for heterosexually active women and men – vaginal, urine • For patients on F/TAF, assess weight, triglyceride and cholesterol levels 	

¹ adolescents weighing at least 35 kg (77 lb)

² Because most PWID are also sexually active, they should be assessed for sexual risk and provided the option of CAB for PrEP when indicated

³ Sexually transmitted infection (STI): Gonorrhea, chlamydia, and syphilis for MSM and transgender women who have sex with men including those who inject drugs; Gonorrhea and syphilis for heterosexual women and men including persons who inject drugs

⁴ estimated creatine clearance (eCrCl) by Cockcroft Gault formula ≥ 60 ml/min for F/TDF use, ≥ 30 ml/min for F/TAF use

Neurologic Complications

SEIZURE

- ☀ Intoxication
 - ☀ Cocaine, stimulants
- ☀ Withdrawal syndromes
 - ☀ Alcohol, barbiturates, benzodiazepines
- ☀ Opiates: meperidine

STROKE

- ☀ At younger age than the general population
- ☀ Alcohol, tobacco, cocaine, opioids, methamphetamine, LSD, PCP

Neurologic Complications

WERNICKE ENCEPHALOPATHY

- ◆ Acute complication of **thiamine deficiency**
- ◆ **Classic triad:**
 - ◆ Encephalopathy
 - ◆ Oculomotor dysfunction
 - ◆ Gait ataxia
- ◆ Treatment: IV thiamine before administering glucose

KORSAKOFF SYNDROME

- ◆ Late neuropsychiatric consequence of WE
- ◆ Anterograde and retrograde amnesia
- ◆ Apathy
- ◆ Intact sensorium
- ◆ Confabulation
- ◆ No treatment, rarely recovers

Sleep Disorders - Changes of Sleep Architecture

	Alcohol	Stimulant or cocaine intoxication	Acute cocaine Withdrawal	Subacute cocaine withdrawal	MDMA intoxication	THC intoxication	THC withdrawal
Sleep latency	↓	↑	↑	↓		↑	↑
Total sleep time	↓	↓	↓	↓	↓		
Sleep efficiency	↓		↓	↓			
Slow wave sleep	↓		↓			↓	↓
REM	↓	↓	↑	↓	↓*	↓	↑

Schierenbeck T, et al. Effect of illicit recreational drugs upon sleep: Cocaine, ecstasy and marijuana. *Sleep Medicine Reviews*. 2008;12(5):381-389. Chakravorty S, et al. Alcohol Dependence and Its Relationship With Insomnia and Other Sleep Disorders. *Alcoholism: Clinical and Experimental Research*. 2016;40(11):2271-2282.

Sleep Disorders

- ◆ Negatively affects physical and emotional well-being
- ◆ Increases risk of relapse
- ◆ First-line of treatment is nonpharmacological
- ◆ Sleep hygiene
- ◆ Avoid benzodiazepines and z-drugs

Nonpharmacological Treatments Of Insomnia

- **Mindfulness meditation.** The patient moves into a state of restful, present-moment alertness, which reduces stress and improves self-control.^{33,34}
- **Progressive muscle relaxation.** The patient concentrates on tensing and relaxing groups of muscles.^{8,35}
- **Biofeedback.** The patient becomes aware of physiologic stress responses and how to control them.²⁶
- **CBT for insomnia.** The patient's dysfunctional beliefs and behaviors are modified to improve his or her emotional state.^{26,36}
- **Stimulus control.** The patient reassociates the bedroom with the rapid onset of sleep.³⁷
- **Exercise.** Regular physical activity relieves stress and tires the patient.²⁶
- **Sleep restriction therapy.** The patient limits sleep to a few hours and progressively increases it until the desired amount of sleep time is achieved.²⁶
- **Bright-light therapy.** Exposure to a natural bright light while awake helps promote normal sleep patterns.³⁸
- **Dental devices and continuous positive airway pressure machines.** These devices help the patient with obstructive sleep apnea breathe more easily during sleep.³⁹

Acute Traumatic Injuries

- ◆ Alcohol and other drugs highly associated with traumatic injuries
- ◆ In 2016, 43.6% of people killed in driving accidents tested positive for alcohol and/or other drugs
- ◆ Most common drugs = marijuana, cocaine/methamphetamine, opioids, sedatives


Endocrine and Reproductive

OPIOID INDUCED HYPOGONADISM

- ◆ Prevalence estimated between 19% and 86% in individuals chronically taking opioids

Symptoms:

- ☀ Change in mood
- ☀ Decreased libido/erectile dysfunction
- ☀ Decrease muscle strength
- ☀ Fatigue
- ☀ Osteopenia/osteoporosis
- ☀ Menstrual cycle abnormalities
- ☀ Hot flashes
- ☀ Failure to conceive



Submit Your Feedback on this Session!



- ✓ Scan QR code or visit bit.ly/SESSIONEVAL
- ✓ Choose the session you are reviewing
- ✓ Provide your feedback

Up Next: *Pharmacology and Toxicology*— Lewis S. Nelson, MD